NCT06418711

ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension

TERMINATEDPHASE3INTERVENTIONAL

Trial Details

Start: 2024-09-11Est. Completion: 2025-11-10

Enrollment target: 132 participants

Locations

University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, United States
University of California San Francisco Fresno, Fresno, California, United States
Cedars-Sinai Medical Center, Los Angeles, California, United States
Hoag Hospital, Newport Beach, California, United States
University of California Davis Medical Center, Sacramento, California, United States
University of California San Francisco, San Francisco, California, United States
Santa Barbara Cottage Hospital, Santa Barbara, California, United States
Stanford University, Stanford, California, United States
National Jewish Health, Denver, Colorado, United States
UCONN Health, Farmington, Connecticut, United States
Yale University, New Haven, Connecticut, United States
Georgetown University Hospital, Washington D.C., District of Columbia, United States
The George Washington University Medical Faculty Associates, Washington D.C., District of Columbia, United States
VA Bay Pines, Bay Pines, Florida, United States
St. Francis Sleep, Allergy & Lung Institute, Clearwater, Florida, United States

Nontuberculous Mycobacterial Lung Disease

The incidence of nontuberculous mycobacterial lung disease (NTM-LD) is increasing worldwide and in Eastern Asia. NTM-LD …

Taipei, TaiwanEst. completion Dec 1, 2026

MAC Lung DiseaseTreatment Refractory MAC Lung Disease

This is a pivotal Phase 2/3, double-blind, placebo-controlled study of epetraborole + OBR (Optimized Background Regimen)…

Birmingham, United StatesCompleted Dec 18, 2024

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.